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ABSTRACT
Objectives: The more surgical effort and performing extensive upper abdominal surgery (UAS) are often required to ac-
complish the highest rates of optimally cytoreduction in patients with ovarian cancer. Nonetheless, the rate of complications 
increases with extensive surgery. We have studied the upper abdominal surgery complications by Clavien-Dindo Classi-
fication (CDC) and analyzed parameters affecting post-operative severe complications classified through Clavien-Dindo. 
Material and methods: A retrospective cohort of patients diagnosed with epithelial ovarian cancer from January 1st 2009 to 
April 30th 2016 was evaluated. Patients who underwent at least one UAS procedure with or without optimal cytoreduction 
for epithelial ovarian cancer (stage IIIC–IV or recurrent) were included. Postoperative complications were recorded accord-
ing to the Clavien-Dindo Classification. 
Results: In total, 58 patients were included. There were 120 UAS procedures performed on the 58 patients. Diaphragm 
peritonectomy was the most performed surgery (50%, 29/58), and then the other UAS procedures were liver surgery (39.7%, 
23/58), cholecystectomy (24.1%, 14/58), splenic surgery (24.1%, 14/58), full-thickness diaphragm resection (22.4%, 13/58), 
pancreatic surgery (19%, 11/58), resection of tumor from porta hepatis (17.2%, 10/58), celiac lymph node excision (8.6%, 
5/58), partial gastrectomy (1.7%, 1/58), respectively. Thirteen patients (22.4%) had post-operative grade 3–5 complications 
according to CDC within 30 days after surgery. 
Conclusions: This current study demonstrated that the addition of extensive upper abdominal surgery procedures were not 
associated with increased postoperative severe complications in patients with recurrent or advanced ovarian cancer. These 
procedures are safe and feasible for patients in need and also can be performed with acceptable mortality and morbidity.
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INTRODUCTION
Ovarian cancer is the second most common malignancy 
of reproductive tract in women and epithelial ovarian cancer 
(EOC) is the most fatal gynecologic cancer; the number of 
new cases of ovarian cancer is 11.9 per 100,000 whereas 
the number of deaths is 7.5 per 100,000 [1]. Despite the 
devastating survival statistics compared to other gyneco-
logic cancers, there has been a decline in the mortality rate 
of EOC. Death rates have been falling on average 2.2% each 
year between 2004–2013 and the 5-year survival rate has 
an upward trend, increasing from 33.7% in 1977 to 46.2% 
in 2008, although the majority of ovarian cancer patients 
have metastasis to upper abdominal organs at diagnosis 
and found to have stage III or stage IV disease [1]. Progress 
in life expectancy of ovarian cancer patients can mainly be 
attributed to advances in cytoreductive surgery and imple-
mentation of platin based chemotherapy [2, 3].
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Major developments in medical treatment of EOC are: 
introduction and combination of paclitaxel to platin based 
chemotherapy in 1996 [4]; the emergence of intraperi-
toneal chemotherapy in 2006 [5]; and targeted chemo-
therapies and poly [adenosine diphosphate (ADP)] ribose 
polymerase (PARP) inhibitors recently [6]. The evolution of 
surgical treatment of EOC was towards more radical, exten-
sive procedures that consisted of radical oopherectomy, 
pelvic peritonectomy, bowel resections and anastomo-
sis, and then upper abdominal procedures were added 
to armory of gynecologic oncologists [7]. The concept 
of optimal cytoreduction was changing and brought to 
an end at maximal cytoreduction in order to improve 
overall survival, despite the new medical treatment mo-
dalities [8]. There has been afierce debate over extensive 
maximal debulking surgery versus neoadjuvant treatment. 
However, many studies have shown that primary cytore-
ductive surgery (CRS) aiming no residual disease was the 
most important modifiable prognostic factor affecting 
survival [9–11]. A dedicated gynecologic oncology team 
performing extensive upper abdominal surgery (UAS) such 
as diaphragm stripping and/or resection, liver resection, 
cholecystectomy, splenectomy, distal pancreatectomy, 
resection of tumor from porta hepatis, celiac lymph node 
excision and partial gastrectomy is required to accom-
plish the highest rates of optimally cytoreduction or com-
plete resection [11–13]. The comprehension of CRS and 
the biology of a tumor was established by many reports 
on the impact of CRS and upper abdominal surgery on 
oncological outcomes. However, systematic evaluation 
of complications of upper abdominal surgery is seldom 
studied. Additionally, standardization is required for clas-
sification of surgical complications. There is no consensus 
among gynecologic oncologist on how to report surgical 
complications.
Clavien-Dindo Classification (CDC), mainly used by gen-
eral surgeons, has been proposed to rank a complication 
in an objective, reliable and reproducible manner [14]. The 
point of CDC is mainly on the therapeutic consequences 
of a complication. Therefore, we have studied the upper 
abdominal surgery complications by CDC and analyzed 
parameters affecting post-operative severe complications 
classified through Clavien-Dindo.
MATERIAL AND METHODS 
We obtained Institutional Review Board approval (num-
ber: 04/03/15:55) and then identified all patients with Inter-
national Federation of Gynecology and Obstetrics (FIGO) 
stage IIIC and IV epithelial ovarian cancer or recurrent 
epithelial ovarian cancer who underwent extensive upper 
abdominal surgery at the Suleyman Demirel University Hos-
pital from January 1, 2009 thru April 30, 2016. The medical 
records of all patients were retrospectively reviewed for the 
following data: age, body mass index (BMI) American Society 
of Anesthesiologist (ASA) score, Eastern Cooperative Oncol-
ogy Group (ECOG) performance status, FIGO stage, pre- 
-operative albumin, serum cancer antigen (CA125), hemo-
globin levels, ascites, upper abdominal surgery procedures, 
estimated blood loss, intraoperative blood transfusion, 
duration of surgery, residual disease after surgery, length 
of hospital stay, and finally post-operative complications 
within 30 days and pathologic data. 
We included patients who had undergone at least one 
upper abdominal surgery procedure with or without opti-
mal cytoreduction for epithelial ovarian cancer (FIGO stages 
IIIC–IV or recurrent). We excluded patients who had received 
neoadjuvant chemotherapy or histologically confirmed 
non-epithelial ovarian cancers, low malignant potential 
tumors from the study. 
These patients were classified according to residual 
disease (RD); RD 0: no residual disease, RD 1–10: residual 
disease 1–10 mm, and RD > 10: gross residual disease is 
more than 10 mm. Extensive surgical procedures were 
performed on the upper abdomen included diaphragm 
peritonectomy, full-thickness diaphragm resection, liver 
surgery (partial liver resection or segmental hepatectomy 
or liver capsule metastasectomy), cholecystectomy, splenic 
surgery (splenectomy or resection of tumor on the surface 
of spleen without splenectomy), pancreatic surgery (distal 
pancreatectomy or resection of tumor on the pancreatic 
capsule), partial gastric resection, celiac lymph node exci-
sion, and resection of tumor from porta hepatis. 
We recorded post-operative complications with the 
Clavien-Dindo Classification. We accepted post-operative 
complications or death associated with surgery if occuring 
within 30 days after surgery. Complications were evalu-
ated in five categories depending on their severity in the 
CDC (1: no treatment or simple medical treatment, and 
5: death) (Tab. 1). We subdivided patients into two groups; 
grade 1–2 complications as mild and grade 3–5 as a severe 
group. We focused on those grades with serious clinical 
outcomes. If patients had more than one complication, we 
noted the highest grade complication in the analysis. Ad-
juvant chemotherapy was routinely administered within 
6 weeks of the operation.
Mean, standard deviation, median lowest, highest, 
frequency and ratio values were used in the descriptive 
statistics of the data. The distribution of the variables was 
measured by the Kolmogorov Simirnov Test. Mann-Whitney 
U Test and Independent Sample T Test were used in the 
analysis of quantitative data. The Chi-square test was used 
to analyze qualitative data, and the Fisher test was used 
when the chi-square test conditions were not met. SPSS 
22.0 program was used in the analyzes.
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RESULTS
Fifty-eight patients with EOC who underwent upper 
abdominal surgery at our institution were included in this 
study between January 1, 2009 and April 30, 2016. All pa-
tients underwent cytoreductive surgery by exploratory 
laparotomy. The demographic characteristics and surgical 
outcomes were abstracted in Table 2. 
The mean age was 62.2, mean BMI was 27.6 kg/m2, 
mean ascites volume was 919.3 ml, mean preoperative 
serum hemoglobin level was 12.4 g/dL, mean preopera-
tive serum albumin level was 3.6 g/dL, mean preopera-
tive serum CA125 was 799 u/mL, mean estimated blood 
loss was 387.1 mL, mean operative time was 319.1 minutes 
and mean post-operative hospital stay was 13.4 days. An 
intra-operative blood transfusion was required in 33 pa-
tients (56.8%). 
The most common ECOG performance status score was 
0 (36.2%) and 65.5% of patients had an ASA class of 2. The 
majority of patients had serous histology (87.9%) and grade 
3 tumors (67.3%). 
Thirty-two out of 58 patients (55.2%) had primary dis-
ease and 26 patients (44.8%) had recurrent disease. Ac-
cording to the results of cytoreductive surgery, no gross 
residual disease after surgery was in 58.6% (n: 34/58, RD 
0), gross residual disease < 10 mm in 12.1% (n: 7/58, RD 
1–10mm), and gross residual disease > 10 mm in 29.3% 
(n: 17/58, RD > 10 mm). In patients who underwent debulk-
ing surgery was primary cytoreduction in 55.2% (32/58), 
secondary cytoreduction in 31.1% (18/58), tertiary cytore-
duction in 13.7% (8/58) of cases respectively. Twenty-seven 
out of 32 patients (84.3%) who had primary disease was 
stage IIIC and 5 patients (15.7%) were stage VI according to 
FIGO classification. 
There were 120 UAS procedures performed on the 
58 patients, and multiple procedures were performed in 
many of patients. Diaphragm peritonectomy was the most 
Table 1. Clavien-Dindo Classification of surgical complications
Grade Definition
Grade I
Any deviation from the normal course without the need 
for pharmacological treatment or surgical, endoscopic and 
radiologic interventions. Allowed therapeutic regimens 
are: drugs as antiemetics, antipyretics, analgetics, diuretics, 
electrolytes and physiotherapy. This grade also includes 
wound infections opened at the bedside
Grade II
Requiring pharmacological treatment with drugs other 
than such allowed for grade I complications. Blood 
transfusions and total parenteral nutrition are also included
Grade III Requiring surgical, endoscopic or radiological intervention
IIIA Intervention not under general anesthesia
IIIB Intervention under general anesthesia
Grade IV Life-threatening complication (including CNS complications)* requiring IC/ICU management
IVA Single organ dysfunction (including dialysis)
IVB Multiorgan dysfunction
Grade V Death of a patient
*Brain hemorrhage, ischemic stroke, subarachnoid bleeding, but excluding 
transient ischemic attacks; CNS — central nervous system; IC — intermediate 
care; ICU — intensive care unit
Table 2. Patient and clinical characteristics
Min–max Mean + SD/N–%
Age [years] 42.0–92.0 62.2 + 10.6
BMI [kg/m2] 18.0–34.4 27.6 + 4.1
Preoperative serum hemoglobin 
[g/dL] 9.2–15.4 12.4 + 1.4
Preoperative serum albumin 
[g/dL] 1.6–4.8 3.6 + 0.6
Preoperative serum CA125 [u/mL] 11.0–5005.0 799.0 + 1140.1 
Ascites volume [mL] 0–7000.0 919.3 + 1490.1
Operative time [min] 140.0–570.0 319.1 + 116.9 
Length of hospitalization [days] 5.0–42.0 13.4 + 8.2
Estimated blood loss [mL] 100–1700.0 387.1 + 332.7
Intra-operative units of blood 
transfused 33 56.8
ECOG performance status 
0
1
2
3
21 36.2
16 27.6
12 20.7
9 15.5
ASA score
1
2
3
 
3 5.2 
38 65.5
17 29.3
Cytoreduction 
Primary 
Secondary
Tertiary 
32 55.2
18 31.1
8 13.7
FIGO stage 
IIIC
IV
Recurrent disease 
27 46.6
5 8.6
26 44.8
Residual disease 
RD 0
RD 1–10 mm
RD > 10 mm
34 58.6
7 12.1
17 29.3
Histology 
Serous
Endometrioid
Mucinous
Carcinosarcoma
Transitional
51 87.9
3 5.2
1.7
3.5
1 1.7
Tumor grade 
1
2
3
7 12.1
12 20.6
39 67.3
PO — postoperative; BMI — body mass index; ASA — American Society 
of Anesthesiologist; ECOG — Eastern Cooperative Oncology Group; FIGO 
— International Federation of Gynecology and Obstetrics; CA125 — cancer 
antigen; RD — residual disease; SD — standard deviation
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performed surgery (50%, 29/58), and then the other UAS 
procedures were liver surgery (39.7%, 23/58), (right pos-
terior bisegmentectomy (segment 6–7); 1/58, intraparen-
chymal tumor resections; 10/58, liver capsule metasta-
sectomy; 12/58), cholecystectomy (24.1%, 14/58), splenic 
surgery (24.1%, 14/58) (splenectomy; 12/58, resection of 
the tumor on the surface of spleen; 2/58), full-thickness 
diaphragm resection (22.4%, 13/58), pancreatic surgery 
(19%, 11/58) (distal pancreatectomy; 4/58, resection of 
tumor on the pancreatic capsule; 7/58), resection of tu-
mor from porta hepatis (17.2%, 10/58), celiac lymph node 
excision (8.6%, 5/58), partial gastrectomy (1.7%, 1/58), 
respectively. Other surgical procedures implemented 
to patients were hysterectomy, unilateral/bilateral sal-
pingo-oophorectomy, pelvic lymph node dissection, 
para-aortic lymph node dissection, omentectomy, peri-
tonectomy, small bowel resection, large bowel resection, 
ileostomy, appendectomy, cardiophrenic lymph node 
dissection, VATS (video assisted thoracoscopic surgery), 
IP (intraperitoneal) catheter, and HIPEC (hyperthermic 
intraperitoneal chemotherapy) (Tab. 3).
Thirteen patients (22.4%) had post-operative grade 
3–5 complications according to Clavien-Dindo Classification 
within 30 days after surgery (Tab. 4). Ten patients (17.2%) 
were reported as grade 3 complication, 1 patient (1.7%) was 
reported as grade 4 complication, and 2 patients (3.5%) were 
reported as grade 5 complication. Grade 3 complications 
were treated surgical, endoscopic or radiological interven-
tion. Grade 4 complication was a life-threatening complica-
tion and treated at intensive care unit. 
Two patients had grade 5 complications (mortalities) 
within 30 days of surgery (3,5%). The first patient died 
due to short bowel syndrome in the 28th post-operative 
day; she was a 49-year-old patient with an ECOG per-
formance status of 2 who underwent multiple surgical 
procedures (right diaphragm peritonectomy, splenectomy, 
distal pancreatectomy, total colon resection, resection of 
the small intestine segment after the 70th cm of the treitz 
ligament, jejunostomy, HIPEC and RD 0 tertiary cytoreduc-
tion) for recurrent serous ovarian carcinoma. The second 
patient died due to acute cardiopulmonary failure in the 
5th post-operative day; she was an 87-year-old patient with 
an ECOG performance status of 3 and cardiac failure who 
underwent multiple surgical procedures (total abdomi-
nal hysterectomy with bilateral salpingo-oophorectomy, 
splenectomy, cholecystectomy, distal pancreatectomy, 
porta hepatis disease resection, total colectomy, ileos-
tomy and optimal cytoreduction) for a stage 4 serous 
ovarian carcinoma. The patient’s status was stable until 
the third postoperative day. On the third postoperative 
day, respiratory arrest occurred suddenly. She was taken to 
the intensive care unit and was connected to a ventilator 
Table 3. Data of surgical procedures implemented to patients
Patients (N: 58) 
n %
Upper abdominal surgery procedures (n: 120)
Diaphragm peritonectomy 29/58 50
Full-thickness diaphragm resection 13/58 22.4
Splenic surgery 14/58 24.1
Pancreatic surgery 11/58 19.0
Cholecystectomy 14/58 24.1
Partial gastrectomy 1/58 1.7
Liver Surgery 23/58 39.7
Celiac lymph node resection 5/58 8.6
Porta Hepatis disease resection 10/58 17.2
Other procedures
Hysterectomy 34/58 58.6
Unilateral/bilateral salpingo-oophorectomy 34/58 58.6
Pelvic lymph node dissection 25/58 43.1
Para-aortic lymph node dissection 24/58 41.3
Omentectomy 39/58 67.2
Peritonectomy 29/58 50
Small bowel resection 13/58 22.4
Large bowel resection 21/58 36.2
Ileostomy 2/58 3.4
Colostomy 4/58 6.9
Anastomosis 19/58 32.7
Appendectomy 14/58 24.1
Cardiophrenic lymph node dissection 1/58 1.7
VATS 7/58 12.1
IP catheter 5/58 8.6
HIPEC 5 /58 8.6
VATS — video assisted thoracoscopic surgery; IP — intraperitoneal;  
HIPEC — hyperthermic intraperitoneal chemotherapy
Table 4. Post-operative grade 3–5 complications according to 
Clavien-Dindo Classification
Type of complication UAS Patients (N: 58%)
Anastomotic insufficiency 2/58 3.5
Short bowel syndrome* 1/58 1.7
Pleural effusion 1/58 1.7
Pneumothorax 1/58 1.7
Pulmonary embolism 1/58 1.7
Postop bleeding 1/58 1.7
Acute cardiopulmonary failure* 1/58 1.7
Intra-abdominal abscess 1/58 1.7
Wound infection 2/58 3.5
Evisceration 2/58 3.5
Total complication 13/58 22.4
*Postoperative 30-day mortality (3.5%); UAS — Upper Abdominal Surgery
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device and monitored. Her status worsened and she died 
on postoperative day 5.
We analyzed the parameters for prediction of the major 
postoperative complication and mortality after extensive 
upper abdominal surgery. There was no statistical differ-
ence in age, BMI, ascites, preoperative serum hemoglobin 
level, preoperative serum albumin level, preoperative serum 
CA125 level, estimated blood loss, operative time, ECOG per-
formance status score, ASA score, FIGO stage and residual 
disease between complicated and uncomplicated patients 
(p > 0.05). Only the length of the post-operative hospital 
stay was statistically significant between complicated and 
uncomplicated patients (p < 0.05) (Tab. 5).
No statistical difference was found between the length 
of the post-operative hospital stay and the types of upper 
abdominal surgical procedures (p > 0.05) (Tab. 6).
There was also no statistical difference in upper abdomi-
nal surgery procedures between complicated and uncom-
plicated patients (p > 0.05). Only diaphragm peritonectomy 
was statistically significant (p < 0.05) (Tab. 7). 
DISCUSSION
The amount of residual tumors after surgery in patients 
with advanced stage cancer is closely related to disease free 
and overall survival [11]. Ovarian cancer tends to spread to the 
upper abdominal anatomic sites and organs and therefore up-
per abdominal surgery has a key role to achieve the optimally 
cytoreduction rate [15]. There are very few studies to indicate 
the complication rate in patients with extensive upper ab-
dominal surgeries. Kuhn et al. [12] reported that the rate of 
perioperative serious complication increased in patients with 
advanced ovarian cancer who underwent UAS compared to 
standard surgery for tumor debulking. Chi et al. demonstrated 
that the rate of postoperative major complications in patients 
underwent extensive UAS was 22% and the rate of postop-
erative mortality was 1.4%. This postoperative mortality and 
morbidity rate was acceptable [16]. In a population-based 
systematic review an average postoperative mortality after 
primary cytoreductive surgery for advanced stage epithelial 
ovarian cancer was reported as 2.5–3.7% [17]. In our study, 
the mortality rate was 3.4% and was similar to the literature. 
Table 5. Comparison of parameters between patients with or without severe complications
PO severe complication 
no
PO severe complication 
yes p
Mean + SD/n–% Min–Max Mean + SD/n–% Min–Max
Age [years] 61.5 + 10.2 42–92 64.5 + 12.1 45–87 0.355
BMI [kg/m2] 27.7 + 3.8 18–34  27.2 + 5.0 21–34 0.532
Preoperative serum hemoglobin [g/dL] 12.4 + 1.3 10–15  12.4 + 1.8 9–15 0.881
Preoperative serum albumin [g/dL] 3.7 + 0.7 1.6–4.8 3.5 + 0.5 2.6–4.2 0.170
Preoperative serum CA125 [u/mL] 827.8 + 1190.5 11–5005 699.2 + 981.4 22–3372 0.758
Ascites volume [mL] 815 + 1454 0–7000 1281 + 1617 0–4000 0.665
Operative time [min.] 313.8 + 118.4 140–570 337.7 + 114.4 180–560 0.520
Length of hospitalization [days] 11.0 + 4.4 5–24 21.9 + 12.0 5–42 0.001
Estimated blood loss [mL] 353.3 + 282.7 100–1300 503.8 + 462.1 100–1700 0.285
ECOG performance status
0 16 35.6% 5 38.5%
0.393
1 14 31.1% 2 15.4%
2 9 20.0% 3 23.1%
3 6 13.3% 3 23.1%
ASA score
1 3 6.7% 0 0.0%
0.8962 29 64.4% 9 69.2%
3 13 28.9% 4 30.8%
FIGO Stage
3C 22 48.9% 5 38.5%
0.6004 2 4.4% 3 23.1%
Recurrent 21 46.7% 5 38.5%
Residual Disease
No Visible 27 60.0% 7 53.8%
0.2101–10 mm 3 6.7% 4 30.8%
> 10 mm 15 33.3% 2 15.4%
T-test, Mann-Whitney U test, Chi-square test; PO — postoperative; BMI — body mass index; ASA — American Society of Anesthesiologist; ECOG — Eastern Cooperative 
Oncology Group; FIGO — International Federation of Gynecology and Obstetrics; CA125 — cancer antigen; SD — standard deviation
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In a previous study, the rate of postoperative major 
complications (grade 3–5) was reported as 19.8% in pa-
tients underwent UAS [18]. In our study, the rate of severe 
postoperative complications (grade 3–5) was 22.4% and 
was compatible with this study.
In recent studies, liver surgery, splenectomy, pancreatic 
surgery, cholecystectomy, celiac lymphadenectomy and 
resection tumor from porta hepatis were reported as strong 
predictive factors for postoperative severe complications 
during cytoreductive surgery for advanced ovarian cancer 
[19–22]. We did not find any correlation between these 
procedures and postoperative severe complications. In our 
study, only diaphragm peritonectomy was associated with 
postoperative severe complications. 
In the literature, the incidence of postoperative pleural 
effusion after diaphragmatic surgery as part of ovarian can-
cer debulking surgery ranged from 10% to 59% [23–26]. 
There is no consensus about use of a chest tube when the 
pleural space is opened during diaphragm surgery. Some 
authors do not recommend prophylactic use of a chest tube 
during diaphragm resection [18, 24–28], on the contrary, 
some authors routinely recommend chest tube placement 
[29–32]. Eisenhauer et al. [24] reported that the postopera-
tive pleural effusion developed in 60% of the patients who 
underwent diaphragm surgery for advanced mullerian can-
cer and 15% of these patients required a postoperative chest 
tube placement or thoracentesis. In another study, the rate 
of postoperative pleural effusion following diaphragmatic 
peritonectomy with ovarian carcinoma was 30%, and 12.5% 
of these patients were treated with thoracentesis or chest 
tube placement to manage symptomatic pleural effusions 
[25]. In these two studies, routine use of chest tubes were 
not recommended when the pleural space is opened. In con-
trast, Chereau and colleagues did not place a chest tube in 
patients whose pleural cavity was opened during diaphragm 
surgery with stage III/IV ovarian cancer (38%) and the rate 
of postoperative chest tube placement was 27%. Therefore, 
at the end of this study period, they decided to consist-
Table 7. Comparison of postoperative severe complications and 
types of surgical procedures
PO severe 
complication 
no
PO severe 
complication 
yes p
n % n %
Diaphragm Resection 11 24.4 2 15.4 0.490
Diaphragm 
Peritonectomy 19 42.2 10 76.9 0.028
Splenic Surgery 9 20.0 5 38.5 0.171
Cholecystectomy 12 26.7 2 15.4 0.402
Gastric Surgery 0 0.0 1 7.7 0.224
Pancreatic Surgery 7 15.6 4 30.8 0.118
Liver Surgery 16 35.6 7 53.8 0.235
Porta Hepatis Disease 
Resection 6 13.3 4 30.8 0.143
Celiac Lymph Node 
Resection 4 8.9 1 7.7 1.000
PO — postoperative, x2 chi-square test (Fisher exact test)
Table 6. Comparison of length of hospital stay and types of surgical procedures
Length of Hospital Stay
Min–Max Median Mean + SD p
Diaphragm Resection No
Yes
5.0–42.0
8.0–33.0 
11
12 
13.2 + 8.4
14.2 + 7.5 0.437
Diaphragm Peritonectomy No
Yes
5.0–24.0
5.0–42.0
10
12
10.8 + 4.2
16.1 + 10.2 0.057
Splenic Surgery No
Yes
5.0–42.0 
5.0–33.0
11
11
13.4 + 8.2
13.7 + 8.2 0.827
Cholecystectomy No
Yes
5.0–42.0
5.0–24.0
11
11
13.8 + 8.9
12.2 + 5.1 0.956
Gastric Surgery No
Yes
5.0–42.0
28.0–28.0
11
28
13.2 + 8.0
28.0 + – 0.142
Pancreatic Surgery No
Yes
5.0–42.0
5.0–33.0
10
13
12.8 + 8.0
16.1 + 8.9 0.164
Liver Surgery No
Yes
5.0–38.0
5.0–42.0
11
12
12.7 + 7.0
14.7 + 9.8 0.566
Porta Hepatis Disease Resection No
Yes
5.0–42.0
5.0–24.0
11
12
13.6 + 8.6
12.8 + 5.6 0.965
Celiac Lymph Node Resection No
Yes
5.0–42.0
8.0–18.0
11
11
13.5 + 8.5
12.4 + 4.4 0.813
Mann-Whitney U test
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ently place a chest tube [31]. Einenkel et al. [32] reported 
a high rate of postoperative chest tube placement (18%) and 
recommended use of chest tubes during diaphragm resec-
tion. In our study, we routinely placed a chest tube during 
diaphragm resection (22.4%) and necessity postoperative 
chest tube was 0% after diaphragm resection. We placed 
postoperative chest tubes because of symptomatic pleural 
effusion and pneumothorax in only 2 patients (3.4%) whose 
were not performed diaphragm surgery.
Langstraat et al. [33] showed that low albumin level, 
emergent surgery, advanced age and stage IV disease 
were associated with poor surgical outcomes in multivari-
ate analysis. Besides, they observed that increased surgical 
complexity did not increase the risk of postoperative major 
complications. In light of this information, extensive surgery 
should not be avoided in patients who require complex 
surgeries. 
There are some scoring systems to predict postoperative 
complications. However, these scoring systems are neglect-
ed if you can completely remove the tumor in patients with 
advanced stage cancer [34]. Because, the maximal cytore-
ductive surgery is the most important prognostic factor for 
overall survival in patients with advanced ovarian cancer. 
Ataseven et al. [35] reported that preoperative serum 
albumin level was a predictive factor for severe postopera-
tive complications (grade 3–5). However, in another study 
preoperative serum, albumin levels were not associated 
with severe postoperative complications [16]. We didn’t 
observed any significant relationship between serum al-
bumin levels in patients with and without postoperative 
severe complications. 
Chi et al. analyzed predictive factors for the risk of severe 
postoperative complications in patients underwent UAS. Pa-
rameters such as BMI, age, ASA score, FIGO stage, and pre-
operative CA-125 levels were found unrelated. However, 
ascites volume, estimated blood loss and operative time 
were reported as predictive factors [16]. In a recent study, 
BMI was reported as an independent risk factor for severe 
postoperative complications and mortality in patients un-
derwent primary surgical debulking for ovarian cancer [35]. 
However, we did not find a correlation between these predictive 
factors and severe postoperative complications in our study.
Benedetti Panici et al. [18] showed that the types of sur-
gical procedures (diaphragmatic, pancreatic, gastric resec-
tion and splenectomy) were significantly related to a longer 
postoperative stay. In our study, there was no correlation 
between the types of upper abdominal surgery procedures 
and the length of hospital stay. However, it was longer in 
patients with severe complication, this result may be due 
to longer treatment process. 
In conclusion, this current study demonstrated that 
the addition of extensive upper abdominal surgery pro-
cedures were not associated with increased postoperative 
severe complications in patients with recurrent or advanced 
ovarian cancer. These procedures are safe and feasible for 
patients in need and also can be performed with acceptable 
mortality and morbidity. 
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